Skip to main content

PRESS RELEASES

Date Title  
01/15/19
- Eric Shaff , previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz , M.D., to continue to serve as Chairman - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc .
01/03/19
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc .

Back to top